[HTML][HTML] Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …
United States and worldwide, despite recent improvements in cancer management. CRC …
BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
KK Ciombor, JH Strickler, TS Bekaii-Saab… - Journal of Clinical …, 2022 - ascopubs.org
BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …
Clinical activity of mitogen-activated protein kinase–targeted therapies in patients with non–V600 BRAF-mutant tumors
PURPOSE Non-V600 mutations comprise approximately 35% of all BRAF mutations in
cancer. Many of these mutations have been identified as oncogenic drivers and can be …
cancer. Many of these mutations have been identified as oncogenic drivers and can be …
[HTML][HTML] BRAF mutated colorectal cancer: New treatment approaches
J Molina-Cerrillo, M San Román, J Pozas… - Cancers, 2020 - mdpi.com
Colon cancer is one of the most frequently diagnosed malignancies in adults, considering
both its incidence and prevalence. Anatomically, the right colon is considered as being from …
both its incidence and prevalence. Anatomically, the right colon is considered as being from …
Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer
Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are
ineffective in all cases. The genomic profile and biomarkers associated with the process are …
ineffective in all cases. The genomic profile and biomarkers associated with the process are …
[HTML][HTML] Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma
AJ Penning, A Al-Ibraheemi, M Michal, BT Larsen… - Modern Pathology, 2021 - Elsevier
Infantile fibrosarcoma (IFS)/cellular congenital mesoblastic nephroma (cCMN) commonly
harbors the classic ETV6-NTRK3 translocation. However, there are recent reports of …
harbors the classic ETV6-NTRK3 translocation. However, there are recent reports of …
Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts
E Osterlund, A Ristimäki, MJ Mäkinen… - … Journal of Cancer, 2024 - Wiley Online Library
Abstract BRAF‐V600E mutation (mt) is a strong negative prognostic and predictive
biomarker in metastatic colorectal cancer (mCRC). Non‐V600Emt, designated atypical …
biomarker in metastatic colorectal cancer (mCRC). Non‐V600Emt, designated atypical …
Molecular targets for the treatment of metastatic colorectal cancer
Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and
genetic characteristics, allowing the development of therapeutic strategies, based on …
genetic characteristics, allowing the development of therapeutic strategies, based on …
Update on emerging therapies for advanced colorectal cancer
Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to
increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is …
increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is …
SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors
Y Nakamura, T Fujisawa, H Taniguchi… - Cancer …, 2021 - Wiley Online Library
Comprehensive genomic profiling enables the detection of genomic biomarkers in
advanced solid tumors. However, efficient patient screening for the success of precision …
advanced solid tumors. However, efficient patient screening for the success of precision …